N-extended photoprotein obelin to competitively detect small protein tumor markers

Biochem Biophys Res Commun. 2022 Apr 2;598:69-73. doi: 10.1016/j.bbrc.2022.02.011. Epub 2022 Feb 6.


Two variants of Ca2+-regulated photoprotein obelin, extended from the N-terminus with small tumor markers - melanoma inhibitory activity protein (MIA) and survivin, one of the protein inhibitors of apoptosis, were designed, obtained and studied. Both domains in the obtained hybrid proteins exhibit the properties of the initial molecules: the main features of Ca2+-triggered bioluminescence are close to those of obelin, and the tumor markers' domains are recognized and bound by the corresponding antibodies. The obtained hybrids compete with the corresponding tumor markers for binding with antibodies, immobilized on the surface and their use has been shown to be promising as bioluminescent labels in a one-stage solid-phase competitive immunoassay.

Keywords: Competitive assay; Genetic fusion; Photoprotein obelin; Tumor marker.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / blood
  • Extracellular Matrix Proteins / blood*
  • Extracellular Matrix Proteins / genetics
  • Extracellular Matrix Proteins / immunology
  • Humans
  • Immunoassay / methods*
  • Limit of Detection
  • Luminescent Measurements
  • Luminescent Proteins* / genetics
  • Luminescent Proteins* / metabolism
  • Neoplasm Proteins / blood*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology
  • Protein Engineering / methods
  • Recombinant Fusion Proteins / chemistry
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / metabolism
  • Survivin / blood*
  • Survivin / genetics
  • Survivin / immunology


  • BIRC5 protein, human
  • Biomarkers, Tumor
  • Extracellular Matrix Proteins
  • Luminescent Proteins
  • MIA protein, human
  • Neoplasm Proteins
  • Recombinant Fusion Proteins
  • Survivin
  • obelin